hcv ns5b polymerase

IDX184 is a potent, orally active, targeted HCV polymerase inhibitor and nucleoside polymerase.IDX184 effectively inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM). IDX184 is a liver-targeted nucleotide prodrug with anti-HCV activity that inhibits HCV NS5B polymerase and can be used in combination with pegylated interferon-α2a and ribavirin for the primary treatment of chronic hepatitis C. It has been shown to inhibit HCV polymerase and nucleoside polymerase.

Setrobuvir (ANA-598) is an orally active, highly selective non-nucleoside HCV NS5B polymerase inhibitor that inhibits new RNA synthesis and primer extension, with IC₅₀ values ranging from 4 to 5 nM. Setrobuvir exhibits high binding affinity for SARS-CoV-2 RdRp and induces inhibition of RdRp. Setrobuvir is suitable for Antiviral drugs studies.

Methyl 2-amino-5-bromobenzoate (Methyl 5-Bromoanthranilate) is a hepatitis C virus NS5b RNA polymerase inhibitor with antimicrobial activity that inhibits Pseudomonas aeruginosa infections and is involved in the production of many virulence factors and biofilm formation.

Mericitabine (R-7128) is a nucleoside HCV NS5B polymerase inhibitor. It acts as an RNA chain terminator and prevents the elongation of RNA transcripts during replication.

Tegobuvir (GS 333126) is a specific and covalent HCV NS5B polymerase inhibitor.

TMC647055 Choline Hydroxide Salt is a novel and potent non-nucleoside inhibitor of the HCV NS5B polymerase which potentially for the treatment of HCV infection. It has nanomolar cellular potency (EC(50) of 82 nM) with minimal associated cell toxicity (CC(

Nesbuvir is a selective hepatitis C virus (HCV) nonstructural protein 5B (NS5B) RNA-dependent polymerase inhibitor.Nesbuvir has an IC50 of 9 nM against hepatocellular carcinoma cells containing 1b HCV replicons.

VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.

HCVNS5B polymerase-IN-2 (Compound 298) is an inhibitor of the Ns5b polymerase. It holds potential for research into the treatment of hepatitis C virus (HCV) infections.

HCVNS5B polymerase-IN-3 (Compound 30a) is an inhibitor of the hepatitis C virus NS5B polymerase. It demonstrates anti-HCV activity with an EC50 of 0.23 μM in Huh7 replicon cell lines, showing no significant cytotoxicity. HCVNS5B polymerase-IN-3 is applicable in hepatitis C virus research.

Filibuvir (PF-00868554) is a selective and noncovalent inhibitor of HCV NS5B RNA-dependent RNA polymerase. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM.

BILB-1941 (BILB-1941ZW) is an inhibitor of HCV NS5B polymerase and can be used in studies about HCV infection.

JTK-109 is a hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor with an IC₅₀ value of 0.017 μM. JTK-109 inhibits the G1b and G3a subgenomic replicases and the recombinase by targeting the Thumb-1 (T1) allosteric site of the NS5B polymerase. JTK-109 can be used in research on hepatitis C virus and cupovirus.

TMC-649128 PM is a potent nucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase, displaying an EC(50) value of 1.2 muM and showing moderate in vivo bioavailability in rat (F=14%).

PSI-6206 (RO 2433) (RO2433) is a selective HCV RNA polymerase inhibitor.

Sofosbuvir (GS 7977) is a uridine monophosphate analog inhibitor of hepatitis C virus (HCV) polymerase NS5B that is used as an antiviral agent in the treatment of chronic hepatitis C.

PSI-6130 (R 1656) is a potent and selective HCV NS5B polymerase inhibitor. PSI-6130 inhibits HCV replication with a mean IC50 of 0.6 μM.

Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the HCV NS5B RNA-dependent RNA polymerase, inhibiting recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 (IC50 < 28 nM).

Galidesivir triphosphate is a substrate for viral RNA-dependent RNA polymerase (RDRP), resulting in termination of viral RNA replication and thus serves as an antiviral. Galidesivir triphosphate inhibits HCV NS5B RNA polymerase activity and protects mice against Ebola. Galidesivir triphosphate (Immucillin-A triphosphate) is converted by the prodrug Galidesivir.

PSI-6206 13C,D3 is the deuterium labeled PSI-6206. PSI-6206 (T2117) is a potent and selective HCV NS5B polymerase inhibitor.

3′-Deoxy CTP trisodium is the sodium salt form of 3′-Deoxy CTP. This compound is a nucleotide analog known as a chain terminator. By lacking a 3′-hydroxyl group, it causes chain termination and inhibits the RNA synthesis activity of the HCV non-structural protein (NS5B) polymerase, thereby blocking viral replication. 3′-Deoxy CTP trisodium is utilized in the study of chain termination mechanisms of HCV polymerase and the development of antiviral drugs.

Anti-infective agent 10 (Compound Example 30) is an ns5b polymerase inhibitor that functions as an anti-HCV agent.

3′-Deoxy CTP is a nucleotide analog that functions as a potent chain terminator. By lacking a 3′-hydroxyl group, 3′-Deoxy CTP induces chain termination, thereby inhibiting the RNA synthesis activity of HCV non-structural protein (NS5B) polymerase and halting viral replication. This compound is useful for studying the chain termination mechanism of HCV polymerases and for developing antiviral drugs.

HCV-IN-50 (Compound 2) is a competitive and selective inhibitor of HCV NS5B RNA-dependent RNA polymerase. It exhibits an IC50 of 0.3 μM against the NS5B ΔC21 enzyme, demonstrating superior inhibitory potency compared to the ΔC55 enzyme. HCV-IN-50 possesses antiviral activity, effectively blocking replication of HCV subgenomic replicons, particularly mutant replicons.